Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Poliomyelitis01:17

Poliomyelitis

Poliomyelitis is caused by poliovirus, a small, non-enveloped, positive-sense RNA virus of the Picornaviridae family and Enterovirus genus. Transmission occurs primarily via the fecal-oral route, often through ingestion of contaminated water or food. The virus initially replicates in the oropharynx and intestinal mucosa, particularly in lymphoid tissues such as the tonsils, Peyer’s patches, and regional lymph nodes. Primary viremia follows, allowing dissemination throughout the body.In most...
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
Viruses with RNA Genomes01:29

Viruses with RNA Genomes

RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
Yellow Fever01:18

Yellow Fever

Yellow fever is a viral hemorrhagic disease caused by the yellow fever virus (YFV), a member of the Flaviviridae family. It is transmitted primarily by Aedes and Haemagogus mosquitoes in tropical and subtropical regions of Africa and South America. After transmission through a mosquito bite, the virus initially replicates in skin-resident immune cells such as dendritic cells and macrophages. These cells then migrate to the lymph nodes, where viral replication increases, eventually leading to...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Role of HBV genotype, monitoring, and events after cessation of nucleos(t)ide analogue therapy.

Journal of hepatology·2026
Same author

Nucleos(t)ide analogue therapy for EASL immune-tolerant phase hepatitis B.

Gut·2025
Same author

Letter to the Editor: HBV DNA level of genuine immune-tolerant patients.

Hepatology (Baltimore, Md.)·2025
Same author

Perspectives on the Issues of Indeterminate/Gray Zones of Chronic Hepatitis B Virus Infection.

Gastroenterology·2025
Same author

Switching to Entecavir >3 Months Before the End of Tenofovir-Based Therapy in Hepatitis B e Antigen-Negative Patients May Reduce Early Relapse and Hepatitis Flare.

The American journal of gastroenterology·2025
Same author

Letter: No Biochemical Relapse Is Associated With the Highest Off-Therapy HBsAg Loss Rate.

Alimentary pharmacology & therapeutics·2025
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
関連記事をすべて見る

関連する実験動画

Updated: Jun 25, 2026

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA
04:11

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA

Published on: December 15, 2023

B型肝炎ウイルス感染症

Yun-Fan Liaw1, Chia-Ming Chu

  • 1Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan.

Lancet (London, England)
|February 17, 2009
PubMed
まとめ
この要約は機械生成です。

ワクチンのおかげでB型肝炎の感染率は低下しているが,慢性的な症例は続いている. 現在の治療法はウイルスを抑制するが,滅多に排除しないため,より良い結果のために新しい薬の開発が必要となる.

さらに関連する動画

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

関連する実験動画

Last Updated: Jun 25, 2026

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA
04:11

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA

Published on: December 15, 2023

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

科学分野:

  • 肝臓病理学 肝臓病理学
  • ウイルス学 ウイルス学 ウイルス学
  • 免疫学 免疫学とは

背景:

  • B型肝炎の感染は,世界中で3億5000万人以上の個人に影響を与える,重要な世界的な健康問題であり続けています.
  • B型肝炎の慢性感染は,肝硬変や肝細胞癌などの重度の肝疾患のリスクを伴います.
  • B型肝炎ウイルス (HBV) の複製は,免疫主導の肝臓損傷と疾患の進行の主要な要因として認識されています.

研究 の 目的:

  • B型肝炎の治療における現在の状況を見直す.
  • 薬剤耐性を含む既存の治療法の限界を強調する.
  • 新しい治療戦略と医薬品開発の必要性を強調する.

主な方法:

  • B型肝炎ウイルス学,免疫学,自然史に関する科学文献のレビュー.
  • 現在の抗ウイルス治療法の有効性と欠陥の分析.
  • B型肝炎の治療における新興傾向と将来の方向性についての議論.

主要な成果:

  • インターフェロンおよびヌクレオシド/ヌクレオチド類似剤を含む抗ウイルス治療は,HBVの複製を効果的に抑制し,疾患の進行を停止します.
  • 現在の治療法では,ウイルスを完全に排除することはめったにありません.
  • 薬剤耐性は,B型肝炎の長期的な管理における重要な課題です.

結論:

  • 進歩にもかかわらず,慢性B型肝炎は,複雑な世界的な健康問題であり続けています.
  • 既存の治療法では,B型肝炎を抑制しますが,治すことはできず,潜在的な耐性につながる可能性があります.
  • 新薬と治療戦略のさらなる研究と開発は,患者のアウトカムを改善し,ウイルスのクリアランスを達成するために不可欠です.